The latest shared research on Cymbalta
Average Daily Dose, Medication Adherence, and Healthcare Costs among Commercially-Insured Patients with Fibromyalgia Treated with Duloxetine
Abstract from: Mario Cazzola, Luigino Calzetta, Maria Gabriella Matera Expert Opinion on Drug Safety Sep 2010, Vol. 9, No. 5, Pages 783-792: 783-792. Objective: What is the relationship between average daily dose (ADD) of duloxetine, adherence to therapy, and healthcare costs among patients with fibromyalgia? Methods: Employing a retrospective cohort design, this study assessed administrative claims data for commercially-insured fibromyalgia patients who initiated duloxetine in 2006. Initiation was defined as a 90-day clean period without access to duloxetine. Five study cohorts were constructed based on the ADD of duloxetine, calculated from all prescriptions dispensed over the 12-month follow-up period: <30 mg, 30 mg, 31–59 mg, 60 mg, and >60 mg ...
Eli Lilly’s Cymbalta (duloxetine) Benefits from Broad Indication Coverage and Extensive Marketing
Drug Overview Eli Lilly’s Cymbalta (duloxetine), a serotonin and norepinephrine reuptake inhibitor (SNRI), was initially approved in the US in August 2004 for the treatment of major depressive disorder (MDD). The company has since accrued a number of additional indications for Cymbalta, including diabetic peripheral neuropathic pain (DPNP), generalized anxiety disorder (GAD), and most recently in June 2008, as a treatment for fibromyalgia in the US (FDA Approves Cymbalta(R) for the Management of Fibromyalgia, 2008, www2.prnewswire.com). Under the brand name Yentreve, the drug is also indicated for the treatment of women with moderate-to-severe stress urinary incontinence (SUI) in the EU. In ...
